Previous 10 | Next 10 |
Oyster Point Pharma Inc (OYST) Q1 2020 Earnings Conference Call May 11, 2020 8:00 AM ET Company Participants Daniel Lochner – Chief Financial Officer Jeffrey Nau – President and Chief Executive Officer John Snisarenko – Chief Commercial Officer Conference ...
Thinly traded Oyster Point Pharma ( OYST -8.7% ) is down on 30% higher volume, a modest 99K shares, in reaction to topline results from a Phase 3 clinical trial, ONSET-2 , evaluating lead candidate OC-01 (verenicline) nasal spray in patients with mild, moderate and severe dry eye diseas...
The following slide deck was published by Oyster Point Pharma, Inc. in conjunction with their 2020 Q1 earnings Read more ...
ONSET-2 met the prespecified primary endpoint in both doses tested, demonstrating statistically significant improvement in Schirmer’s score from baseline to Week 4 in subjects receiving OC-01 nasal spray versus control (p<0.0001) Key secondary symptom endpoints also met in t...
Oyster Point Pharma (NASDAQ: OYST ): Q1 GAAP EPS of -$0.77 beats by $0.22 . More news on: Oyster Point Pharma, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Announces Positive Results in ONSET-2 Phase 3 Trial of OC-01 Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease ONSET-2 Data Enables NDA Submission in 2H 2020 Cash and Cash Equivalents of $128.6 million as of March 31, 2020 Conference Call and Webcast S...
PRINCETON, N.J., May 04, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced tha...
Gainers: RTIX +50.0% . QTNT +19.6% . SNDX +17.3% . PI +9.2% . More news on: RTI Surgical Holdings, Inc., Quotient Limited, Syndax Pharmaceuticals, Inc., Stocks on the move, , Read more ...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
ONSET-2 Phase 3 Top-Line Data Expected by End of Q2 2020 NDA Submission Expected During 2H 2020 PRINCETON, N.J., March 30, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stag...
News, Short Squeeze, Breakout and More Instantly...
Oyster Point Pharma Inc. Company Name:
OYST Stock Symbol:
NASDAQ Market:
Oyster Point Pharma Inc. Website:
TYRVAYA ® (Varenicline Solution) Nasal Spray Achieved Net Product Revenue of $5.6 Million in Q3 ’ 22 Approximately 34,000 TYRVAYA Prescriptions Filled During the Quarter, with Prescriptions Written by Approximately 6,100 Unique Eye Care Profes...
Tender Offer to Acquire All Outstanding Shares of Oyster Point Pharma for $11.00 per Share, Plus a Contingent Value Right of Up To $2.00 per Share PRINCETON, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”), ...